Mechanism of action
Rabies vaccine contains inactivated rabies virus that stimulates the immune system to produce neutralizing antibodies against the viral glycoprotein. The glycoprotein is the primary surface antigen responsible for viral attachment and entry into host cells, particularly neurons.
Upon vaccination, antigen-presenting cells process the viral antigens and present them to T helper cells, which activate B lymphocytes. These B cells differentiate into plasma cells that produce rabies virus-specific IgG antibodies. Memory B cells are also generated, providing long-term immunity.
The neutralizing antibodies bind to the rabies virus glycoprotein, preventing viral attachment to nicotinic acetylcholine receptors and neural cell adhesion molecules on peripheral nerves. This blocks retrograde axonal transport to the central nervous system, the hallmark of rabies pathogenesis.
Modern rabies vaccines are produced in either human diploid cell culture or purified chick embryo cells and contain no live virus, making them safe for immunocompromised individuals. The inactivated virus cannot replicate but retains sufficient antigenic structure to trigger robust immune responses.
- Post-exposure prophylaxis requires both vaccine and immunoglobulin in previously unvaccinated individuals; previously vaccinated persons need only vaccine boosters.
- Rabies vaccine is administered in the deltoid (adults) or anterolateral thigh (children); never give in the gluteal region due to poor immunogenicity.
- Bat exposure warrants prophylaxis even without visible bite due to tiny teeth; suspect exposure if bat found in room with sleeping person or child.
- Healthy domestic dogs, cats, and ferrets can be observed for 10 days; wild carnivores and bats should prompt immediate prophylaxis.
- Modern cell-culture vaccines (HDCV, PCECV) are safe in pregnancy and immunocompromised patients; post-exposure prophylaxis has no absolute contraindications.
- Rabies immunoglobulin is infiltrated into and around wounds, with remainder given IM at a site distant from vaccine injection.
- Immunocompromised patients receive a 5-dose vaccine series (days 0, 3, 7, 14, 28) with antibody titer verification.
- Once clinical rabies develops, the disease is almost invariably fatal; prevention through timely post-exposure prophylaxis is essential.
Indications
Pre-exposure prophylaxis is indicated for individuals at high risk of rabies exposure, including veterinarians, animal handlers, laboratory workers handling rabies virus, spelunkers exploring bat-inhabited caves, and travelers to rabies-endemic regions with limited access to post-exposure prophylaxis. Pre-exposure vaccination consists of a series administered over several weeks.
Post-exposure prophylaxis is the primary use and is indicated following potential exposure to rabies virus through:
- Bites or scratches from potentially rabid animals, especially bats, raccoons, skunks, foxes, and unvaccinated dogs
- Contamination of mucous membranes or open wounds with saliva or neural tissue from potentially rabid animals
- Bat exposure where a bite cannot be excluded, particularly in sleeping individuals or young children
Post-exposure prophylaxis must be initiated as soon as possible after exposure. For previously unvaccinated individuals, the regimen includes both rabies vaccine and rabies immunoglobulin. Previously vaccinated individuals with documented adequate antibody titers require only booster doses of vaccine without immunoglobulin.
Rabies post-exposure prophylaxis is considered a medical urgency. Once clinical rabies develops, the disease is almost uniformly fatal, with only a handful of survivors ever documented worldwide.
Pharmacokinetics
Rabies vaccine is administered intramuscularly, typically in the deltoid region in adults or the anterolateral thigh in children. Gluteal administration should be avoided as it may result in lower antibody titers.
Following intramuscular injection, antigen is taken up by local dendritic cells and transported to regional lymph nodes where immune activation occurs. Detectable neutralizing antibodies typically appear within seven to ten days after the first dose in immunocompetent individuals.
Pre-exposure immunization schedules vary but commonly involve doses on days zero, seven, and twenty-one or twenty-eight. Antibody titers peak approximately two weeks after the final dose.
Post-exposure prophylaxis in previously unvaccinated individuals follows a schedule with doses administered on days zero, three, seven, and fourteen. A fifth dose on day twenty-eight may be recommended for immunocompromised patients. Rabies immunoglobulin is administered simultaneously with the first vaccine dose but at a different anatomical site.
Previously vaccinated individuals with documented immunity require only two booster doses on days zero and three following exposure. Antibody titers should be checked in individuals at continuous risk of exposure, with boosters given when titers fall below protective levels. The duration of protective immunity following complete vaccination is several years, though routine booster intervals depend on ongoing risk assessment.
Adverse effects
Rabies vaccine is generally well tolerated, with most adverse effects being mild and self-limited.
Common local reactions include:
- Pain, erythema, and swelling at the injection site (occurring in 30-74% of recipients)
- Induration and pruritus at the injection site
Systemic reactions include:
- Headache, malaise, and myalgia
- Nausea and abdominal pain
- Dizziness
- Low-grade fever
Serious adverse effects are rare but include:
- Immune complex-like reactions (serum sickness-like illness) occurring in approximately 6% of individuals receiving booster doses of HDCV vaccine, characterized by urticaria, arthralgia, arthritis, angioedema, nausea, vomiting, and fever, typically developing two to twenty-one days after booster administration
- Guillain-Barré syndrome has been reported rarely, though causation is not firmly established
- Anaphylaxis is extremely rare but has been documented
- Neurologic reactions including encephalitis and transverse myelitis are exceedingly rare
Modern cell-culture vaccines have a much lower incidence of neurologic complications compared to older nerve tissue-derived vaccines, which are no longer used in developed countries. The risk of serious adverse effects is far outweighed by the near-certain fatality of untreated rabies.
Patients should be observed for fifteen minutes after vaccination for immediate hypersensitivity reactions. Symptomatic treatment with analgesics and antipyretics is appropriate for minor reactions.
Contraindications and warnings
For pre-exposure prophylaxis, the only absolute contraindication is a history of severe allergic reaction (anaphylaxis) to a previous dose of rabies vaccine or any vaccine component, including gelatin, neomycin, or other trace elements from the manufacturing process.
For post-exposure prophylaxis, there are no absolute contraindications. Because rabies is almost invariably fatal once clinical disease develops, post-exposure prophylaxis should be administered regardless of pregnancy status, immunocompromised state, or history of reactions to other vaccines. The risk of rabies far exceeds any theoretical vaccine risk.
Special populations:
Pregnancy and lactation: Rabies vaccine is safe during pregnancy and is classified as pregnancy category C only due to lack of controlled studies, not because of demonstrated harm. Post-exposure prophylaxis should never be withheld from pregnant or breastfeeding women. Pre-exposure prophylaxis can be considered if risk of exposure is substantial.
Immunocompromised patients: Individuals with HIV infection, those receiving immunosuppressive therapy, or patients with primary immunodeficiencies should receive the standard post-exposure regimen with an additional fifth dose on day twenty-eight. Antibody titers should be checked to confirm adequate immune response, as seroconversion may be impaired.
Concurrent illnesses: Minor acute illnesses are not contraindications. For pre-exposure prophylaxis in patients with moderate or severe acute illness, vaccination may be deferred, but post-exposure prophylaxis should never be delayed.
Chloroquine and mefloquine may interfere with antibody response when given concurrently with intradermal rabies vaccine administration. If intradermal administration is used for pre-exposure prophylaxis in travelers taking these antimalarials, the intramuscular route should be used instead, or vaccination should be completed before antimalarial therapy begins.
Drug interactions
Rabies vaccine has relatively few clinically significant drug interactions.
Immunosuppressive agents including corticosteroids, chemotherapeutic agents, biologic immunomodulators, and radiation therapy may reduce immune response to rabies vaccine. When possible, elective pre-exposure vaccination should be deferred until immunosuppressive therapy is completed. For post-exposure prophylaxis in immunocompromised patients, vaccination should proceed with an extended five-dose schedule and antibody titers should be verified.
Antimalarials: Chloroquine and related compounds may interfere with the immune response to rabies vaccine when the intradermal route is used. This interaction is not clinically significant with intramuscular administration. Travelers to malaria-endemic regions requiring pre-exposure rabies prophylaxis should receive intramuscular vaccination.
Rabies immunoglobulin must be administered concurrently with the first vaccine dose in previously unvaccinated individuals but should be injected at a different anatomical site. Rabies immunoglobulin provides immediate passive immunity while active immunity from the vaccine develops. Administering immunoglobulin at the same site may reduce vaccine immunogenicity.
Other vaccines: Rabies vaccine can be administered simultaneously with other vaccines at different injection sites without affecting immunogenicity or increasing adverse effects. There is no need to separate rabies vaccination from routine immunizations.
Interference with immune response: Live viral vaccines do not interfere with rabies vaccine response. Killed or inactivated vaccines, toxoids, and immunoglobulins can be given concurrently.
Antibody testing is recommended two to four weeks after completion of the post-exposure series in immunocompromised individuals to ensure adequate seroconversion occurred.
Clinical pearls
Post-exposure prophylaxis essentials: Wound care is critical and includes immediate thorough washing with soap and water, followed by application of virucidal agents such as povidone-iodine. This mechanical cleansing can significantly reduce viral load and is an essential first step in rabies prevention.
Bat exposures require special attention: Any direct contact with a bat, or situations where a bat is found in a room with a sleeping person, unattended child, or intoxicated individual should be treated as potential exposure even without visible bite marks. Bat teeth are small and may leave imperceptible wounds.
Animal observation vs. immediate prophylaxis: Healthy domestic dogs, cats, or ferrets that bite humans can be observed for ten days. If the animal remains healthy during this period, rabies can be excluded and post-exposure prophylaxis can be discontinued. Wild animals (especially raccoons, skunks, bats, and foxes) or animals that cannot be captured should prompt immediate prophylaxis without waiting.
Immunoglobulin infiltration: As much rabies immunoglobulin as anatomically feasible should be infiltrated around and into the wound(s). Any remaining volume is administered intramuscularly at a site distant from vaccine administration. This provides crucial passive immunity during the window before vaccine-induced antibodies appear.
Never delay post-exposure prophylaxis: Even if days or weeks have passed since exposure, prophylaxis should still be initiated. The rabies incubation period is typically one to three months but can range from days to years. No time is too late to start prophylaxis before symptom onset.
Rabies is almost 100% fatal: Only fourteen documented cases of survival from clinical rabies have been reported, mostly following the Milwaukee Protocol, which itself has a high failure rate. Prevention through vaccination is the only reliable intervention.
International travel considerations: Travelers to rabies-endemic regions, particularly in Asia and Africa, should consider pre-exposure prophylaxis if they will have limited access to safe post-exposure prophylaxis. Pre-exposure vaccination simplifies post-exposure management by eliminating the need for immunoglobulin, which may be unavailable or unsafe in resource-limited settings.
Immune response monitoring: Individuals at continuous risk (laboratory workers, veterinarians) should have antibody titers checked every six months to two years depending on risk level, with booster doses given when titers fall below 0.5 IU/mL by rapid fluorescent focus inhibition test.
5 W's of rabies post-exposure prophylaxis: Wound washing (soap and water immediately), Wild animal exposure (immediate prophylaxis), Watch domestic animals (10-day observation), With immunoglobulin (in previously unvaccinated), Within deltoid (vaccine site).
Practice questions
1. A 32-year-old veterinarian presents to the emergency department 4 hours after being bitten on the hand by a stray dog that subsequently escaped. She completed a pre-exposure rabies vaccination series 3 years ago but has not had antibody titers checked. The wound has been thoroughly cleaned. What is the most appropriate post-exposure management?
2. A 7-year-old boy is brought to the clinic after his parents found a bat in his bedroom in the morning. The child was sleeping alone and has no visible bite marks or scratches. The bat escaped and could not be captured for testing. What is the most appropriate management?
3. A 45-year-old woman with HIV infection (CD4 count 150 cells/μL) presents 6 hours after being bitten by a raccoon while hiking. She has never received rabies vaccination. Wound care has been performed. In addition to rabies immunoglobulin, what is the most appropriate rabies vaccination schedule for this patient?
Frequently asked questions
How does rabies vaccine work?
Rabies vaccine contains inactivated rabies virus that stimulates the immune system to produce neutralizing antibodies against the viral glycoprotein. These antibodies prevent the virus from attaching to nerve cells and traveling to the brain. The vaccine induces both immediate antibody production and long-term immunologic memory through B and T cell activation, providing protection against future rabies exposure.
What are the side effects of rabies vaccine?
Common side effects include pain, redness, and swelling at the injection site, occurring in 30-74% of recipients. Systemic reactions include headache, fatigue, muscle aches, and low-grade fever. Serious adverse effects are rare but include immune complex-like reactions (serum sickness) in approximately 6% of individuals receiving HDCV boosters, characterized by hives, joint pain, and fever. Anaphylaxis and neurologic complications are extremely rare with modern cell-culture vaccines.
When should you get rabies vaccine after exposure?
Rabies post-exposure prophylaxis should be initiated as soon as possible after a potential exposure, ideally within hours. However, it should be given regardless of the time elapsed since exposure, even if days or weeks have passed, as long as clinical symptoms have not yet appeared. The rabies incubation period is typically one to three months but can range from days to years, so prophylaxis remains beneficial until symptom onset. Once clinical rabies develops, the disease is almost uniformly fatal.
Is rabies vaccine safe during pregnancy?
Yes, rabies vaccine is safe during pregnancy and should never be withheld for post-exposure prophylaxis in pregnant women. Rabies is almost invariably fatal once clinical disease develops, so the theoretical risk of vaccination is far outweighed by the risk of rabies. No adverse fetal effects have been documented with rabies vaccination during pregnancy. Pre-exposure prophylaxis can also be considered in pregnant women at high risk of exposure.
What is the difference between rabies vaccine and rabies immunoglobulin?
Rabies vaccine induces active immunity by stimulating the body to produce its own antibodies, which takes seven to ten days to develop. Rabies immunoglobulin provides immediate passive immunity by supplying pre-formed antibodies, offering protection during the critical window before vaccine-induced immunity develops. Previously unvaccinated individuals require both for post-exposure prophylaxis: immunoglobulin is infiltrated into wounds for immediate protection, while vaccine is given to establish long-term immunity. Previously vaccinated persons with documented immunity need only vaccine boosters.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J07BG01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.